ctDNA and MRD Advance Toward Clinical Integration in Lymphoma

Minimal residual disease (MRD) assessment and circulating tumor DNA (ctDNA) monitoring are emerging as important tools that may refine clinical management in lymphoma. In an interview with OncLive®, Sarah Rutherford, MD, discussed how ctDNA is…